NCT06498986View on ClinicalTrials.gov

A Study of BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

July 31, 2024

Primary Completion Date

August 31, 2026

Study Completion Date

August 31, 2026

Conditions
Non-small Cell Lung Cancer
Interventions
DRUG

BL-B01D1

Administration by intravenous infusion for a cycle of 3 weeks.

DRUG

Osimertinib Mesylate Tablets

Oral administration, 80mg daily for a cycle of 3 weeks.

Trial Locations (1)

Unknown

RECRUITING

Shanghai East Hospital, Shanghai

All Listed Sponsors
collaborator

Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

INDUSTRY

lead

Sichuan Baili Pharmaceutical Co., Ltd.

INDUSTRY